Surgical oncology. Alternatives to surgery after failure of instillation therapy
- PMID: 20517340
- DOI: 10.1038/nrclinonc.2010.69
Surgical oncology. Alternatives to surgery after failure of instillation therapy
Abstract
Management of high-risk non-muscle-invasive bladder cancer represents a difficult challenge in clinical practice. the dilemma is to decide between an organ-sparing approach or radical cystectomy with the risk of undertreatment or overtreatment for this group of patients. This issue is especially important for patients who have failed previous intravesical therapy.
Similar articles
-
Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Urol Oncol. 2014. PMID: 23628309 Review.
-
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12. Eur Urol. 2013. PMID: 23827737 Review.
-
Management of high-risk non-muscle invasive bladder cancer.Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
-
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17. Eur Urol. 2017. PMID: 27324428
-
Bladder sparing surgery in high-grade bladder cancer.Exp Oncol. 2019 Jun;41(2):160-165. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-2.13207. Exp Oncol. 2019. PMID: 31262149
Cited by
-
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology. 2015 Mar 2;4(4):e1008814. doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137403 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources